Inflammation and Corticosteroid Responsiveness in Severe Asthma (SARP)
Some patients with mild asthma may develop severe asthma. It is not known what makes patients with mild asthma become severe, and we plan to find out why this happens. Patients with severe asthma may have a different type of inflammation in the airway tubes. Patients with severe asthma do not get as much benefit from taking steroid inhalers or tablets compared to asthma patients with mild disease. The study hypothesis is that the inflammation in severe asthma is such that it makes steroids less effective in treating asthma. We will find out what possible abnormalities there are in the blood cells and the bronchoalveolar macrophage cells in the lungs of patients with severe asthma compared to those with mild or moderate asthma.
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Inflammation and Corticosteroid Responsiveness in Severe Asthma|
- Lung function FEV1 [ Time Frame: days ] [ Designated as safety issue: Yes ]
- Suppression of monocyte activation and alveolar macrophage activation by dexamethasone ex-vivo [ Time Frame: Days ] [ Designated as safety issue: No ]
- Effect of corticosteroids on release of cytokines from macrophages [ Time Frame: Once ] [ Designated as safety issue: No ]
- Exhaled NO [ Time Frame: Days ] [ Designated as safety issue: No ]
- Biopsy eosinophils [ Time Frame: Once ] [ Designated as safety issue: No ]
- Sputum eosinophils [ Time Frame: Once ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
endobronchial biopsies and blood specimens.
|Study Start Date:||August 2003|
|Study Completion Date:||May 2008|
|Primary Completion Date:||February 2008 (Final data collection date for primary outcome measure)|
Patients under Steps 4/5 of Asthma Treatment - SIGN/BTS Guidelines
Asthma patients on steps 2/3 of Asthma treatment according to SIGN/BTS Guidelines
Asthma patients on steps 1 of asthma treatment (steroid naive).
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00180661
|Royal Brompton Hospital|
|London, United Kingdom, SW3 6HP|
|Principal Investigator:||Kian Fan Chung, MD||Imperial College London|